Clinical Implementation of suPARnostic® Quick Triage at 7 hospitals in Region Zealand, Denmark
Tue Mar 24 2020
suPARnostic® Quick Triage will now be available for clinical decision making at seven hospitals in Region Zealand, Denmark. The analyses will initially be conducted at Næstved Hospital’s clinical immunology department. The remaining six hospitals in the region will have samples transported for analysis at Næstved Hospital on a daily basis.
Initially the test will be used to help triage patients admitted to the hospital with suspicion of COVID-19 disease.
ViroGates has previously offered free test kits to hospitals in Denmark to test potential COVID-19 patients. We remain committed to combating COVID-19 and will initially supply free test kits to Næstved Hospital for this purpose.
The implementation is not restricted to the COVID-19 situation but will be offered as a general analysis to the seven hospitals in the region. The hospitals in the region are Næstved, Slagelse, Ringsted, Holbæk, Køge, Roskilde and Nykøbing Sj. The total number of beds is 1677 (excluding psychiatric wards).
Acute care services are offered at the hospitals in Køge, Slagelse and Nykøbing Sj.
Following the initial implementation, ViroGates and other hospitals in the region will evaluate the need for additional analysis capacity to be implemented locally at the other hospitals in the region.
CEO Jakob Knudsen, ViroGates, says in a comment: ”At ViroGates, we are proud to help during these difficult times for our hospital system. There is no doubt that the COVID-19 situation forces overburdened healthcare professionals to make even faster triage decisions.
We are confident that suPAR measurements can help identify low-risk COVID-19 patients for discharge and high-risk COVID-19 patients for admission and are pleased that Region Zealand has made an accelerated decision to implement suPARnostic® Quick Triage to help in this important task to combat the COVID-19 outbreak.
Initially, we will supply our products free of charge as our contribution to combating the pandemic.
We are, however, also pleased to note that the regional hospitals will use our products beyond the COVID-19 crisis in their workto assess the overall inflammatory disease status and risk of their patients.”
Medical Director Region Zealand Ph.D. Keld M. Homburg says:“The suPARnostic® Quick Triage will now be available for all departments within hospitals in Region Zealand, Denmark. The Department of Clinical Immunology offers the analysis, having brought forward the implementation due to the extraordinary COVID-19 pandemic.
The aim is to fulfill clinical requirements to include the analysis in the evaluation of patients submitted with this disease.
Moreover, the suPARnostic® Quick Triage will be available for all patients within the regional hospitals whatever the diagnostic purpose. Thus, the implementation also allows patients suffering from rheumatic diseases to be assessed using suPARnostic® Quick Triage testing.”